Ani Pharmaceuticals (ANIP) | Stock Overview & Key Data
Ani Pharmaceuticals Performance Comparison
Stock Range
Today's Range
Low: $89.25
High: $90.86
on August 20, 2025
52 Week Range
Low: $52.50
High: $91.02
on December 19, 2024
on August 19, 2025
All-Time High: $450.00 on May 29, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.9B
EPS
-0.69
P/E Ratio (TTM)
51.63
Forward P/E
15.82
P/B Ratio
4.03
PEG Ratio
-0.14
Div. Yield
N/A
ROE
-2.17%
Beta
0.607
Debt to Equity
136.10
Financial Highlights
Profitability
Gross Margin
64.70%
Operating Margin
7.18%
Profit Margin
-1.37%
Returns and Earnings
Return on Assets (TTM)
1.09%
Return on Equity (TTM)
-2.17%
EBITDA
$65.9M
Net Income (TTM)
$-12.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$35.41
Quarterly Revenue Growth (YoY)
53.10%
Quarterly Earnings Growth (YoY)
53.12%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ani Pharmaceuticals ANIP | 1.90B Small-cap | 1.97% | 37.72% | 49.73% | 50.16% | 62.48% | 46.08% | 137.11% | 188.23% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.42B Large-cap | 1.67% | 2.20% | -10.48% | -2.40% | 3.18% | -1.62% | 56.34% | 31.44% |
| BioCryst BCRX | 1.76B Small-cap | -0.84% | -2.82% | -20.15% | -11.82% | 5.75% | 2.22% | -41.94% | 108.56% |
| BGM BGM | 1.55B Small-cap | 4.97% | -26.53% | -36.76% | -23.28% | -12.64% | 33.68% | 29.26% | -82.13% |
| Harrow HROW | 1.42B Small-cap | 9.76% | 3.10% | 35.09% | 26.34% | 4.57% | -10.52% | 314.88% | 445.86% |
Ownership & Short Interest
Insider Ownership
10.66%
Institutional Ownership
99.34%
Shares Short
2M
Short Ratio
7.17
Short % of Shares Outstanding
12.78%
Average 10-Day Volume
1M
Average 90-Day Volume
554K
Ani Pharmaceuticals Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ani Pharmaceuticals would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ANIP's 52-week high and low?
- In the last 52 weeks, Ani Pharmaceuticals reached a high of $91.02 (on August 19, 2025) and a low of $52.50 (on December 19, 2024).
- What is the market cap and P/E ratio for ANIP?
- Curious about Ani Pharmaceuticals's size and valuation? Its market capitalization stands at 1.90B. When it comes to valuation, the P/E ratio (trailing twelve months) is 51.63, and the forward P/E (looking ahead) is 15.82.
- Does ANIP pay dividends? If so, what's the yield?
- As for dividends, Ani Pharmaceuticals isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ani Pharmaceuticals's main competitors or similar companies to consider before investing?
When looking at Ani Pharmaceuticals, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.42B Healthcare Drug Manufacturers - Specialty & Generic -1.62% 56.34% BioCryst
BCRX1.76B Healthcare Drug Manufacturers - Specialty & Generic 2.22% -41.94% BGM
BGM1.55B Healthcare Drug Manufacturers - Specialty & Generic 33.68% 29.26% Harrow
HROW1.42B Healthcare Drug Manufacturers - Specialty & Generic -10.52% 314.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ani Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ani Pharmaceuticals's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -2.17%, the Debt to Equity ratio from the most recent quarter is 136.10, and its Gross Profit Margin stands at 64.70%.
- What is the recent revenue and earnings growth for ANIP?
- Looking at Ani Pharmaceuticals's growth, its revenue over the trailing twelve months (TTM) was $747M. Compared to the same quarter last year (YoY), quarterly revenue grew by 53.10%, and quarterly earnings saw a YoY growth of 53.12%.
- How much of ANIP stock is held by insiders and institutions?
- Wondering who owns Ani Pharmaceuticals stock? Company insiders (like executives and directors) hold about 10.66% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.34%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.